ライフサイエンスコーパス: chelerythrine

1 ological inhibitors of PKC (calphostin C and chelerythrine).

2 e classical protein kinase C (PKC) inhibitor chelerythrine.

3 abrogated by the protein kinase C inhibitor chelerythrine.

4 s blocked by PKC inhibitors calphostin C and chelerythrine.

5 ertussis toxin, Gi3 antibodies, D609, and by chelerythrine.

6 3) for 10 s UV), which could be inhibited by chelerythrine.

7 D609, and by the protein kinase C inhibitor chelerythrine.

8 rfusion are abolished by PKC inhibition with chelerythrine.

9 is effect was prevented by the coinfusion of chelerythrine.

10 ristoylated zeta inhibitory peptide (ZIP) or chelerythrine.

11 confirm the reported inhibitory activity of chelerythrine.

12 nd blocked by the protein kinase C inhibitor chelerythrine.

13 was blocked by a protein kinase C inhibitor, chelerythrine.

14 on of PKC by IPC was blocked by verapamil or chelerythrine.

15 ttenuated by the treatment with verapamil or chelerythrine.

16 e or the specific protein kinase C inhibitor chelerythrine.

17 D occludes the synaptic depression caused by chelerythrine.

18 /C5 channel activity, which was prevented by chelerythrine.

19 ted with the protein kinase inhibitors H7 or chelerythrine.

20 is abolished by the PKC-selective inhibitor chelerythrine.

21 nted by the protein kinase C (PKC) inhibitor chelerythrine.

22 s increased by CPA and PDBu but decreased by chelerythrine.

23 ed O(2)(.-) generation that was inhibited by chelerythrine.

24 apocynin and the protein kinase C inhibitor chelerythrine.

25 nel opening (NP(o)) and this was reversed by chelerythrine.

26 ne on Isus were blocked by the PKC inhibitor chelerythrine.

27 ion of TRPC6 proteins which was inhibited by chelerythrine, 0 [Ca(2+)](o) and the anti-TRPC1 antibody

28 pplication of the protein kinase C inhibitor chelerythrine (1-10 microM) had no effect on either OAG-

29 Administration of 5 mg/kg of chelerythrine 10 min after the sixth reperfusion on day

30 rbol esters or exposure to the PKC inhibitor chelerythrine (10 microM) each inhibited currents.

31 microM), an MLCK (MLC kinase) inhibitor, or chelerythrine (10 microM), an inhibitor of PKC.

32 roM, 4 min), a phospholipase C inhibitor, or chelerythrine (10 microM, 4 min), a protein kinase C (PK

33 ), and the protein kinase C (PKC) inhibitors chelerythrine (10 micrometer) or PKC 19-36 peptide (1 mi

34 Pretreatment with chelerythrine (10 micromol/L, 45 minutes), a protein kin

35 solution, and was blocked by PKC inhibitors chelerythrine (10 mumol/L) and staurosporine (100 nmol/L

36 and partially restored by the PKC inhibitor chelerythrine (10(-7) M) or the O(-)(2) free radical sca

37 hibitors staurosporine (10(-9) to 10(-7) M), chelerythrine (10(-9) to 5 x 10(-8) M), or calphostin C

38 l]-3-(1H-indol-3-yl) maleimide, 1 microm; or chelerythrine, 10 microm) did not prevent the generation

39 iferase activity was completely inhibited by chelerythrine, 2-aminopurine, genistein, and W-7 and onl

40 Staurosporine (3 microM), chelerythrine (200 microM) and N-ethylmaleimide (1 mM) s

41 ytosolic Ca2+, exposure to the PKC inhibitor chelerythrine (25 microM) and downregulation of PKC by p

42 5 pA/pF), and by the putative PKC inhibitor, chelerythrine (25 micromol/L; -7 +/- 3 pA/pF).

43 The protein kinase C (PKC) inhibitor chelerythrine (3 microM) potentiated Ang II-evoked Icat1

44 300 U/mL), PEG-SOD+PEG-catalase (1000 U/mL), chelerythrine (3 micromol/L), or tetrahydrobiopterin (20

45 itoK(ATP) channel blocker (56.5+/-2.7%), and chelerythrine (5 mg/kg IV), an effective PKC inhibitor (

46 The higher dose of chelerythrine (5 mg/kg; group X, n = 5) prevented the tr

47 The protein kinase C (PKC) inhibitor chelerythrine (5 microM) significantly reduced hyposmoti

48 C) inhibitors, calphostin C (0.5 microM) and chelerythrine (5 microM), or a nitric oxide synthase (NO

49 nhibition with staurosporine (2 x 10-6M) and chelerythrine (5 x 10-5M) on endothelin-1-induced pulmon

50 Of the protein kinase inhibitors tested, chelerythrine, 6-dimethylaminopurine, H-89, K252a, ML-9,

51 D145065 (10 microM) and by the PKC inhibitor chelerythrine (8 microM).

52 effects were unaffected by the PKC inhibitor chelerythrine (8 microM).

53 Chelerythrine, a natural benzophenanthridine alkaloid, h

54 Chelerythrine, a PKC inhibitor, abolished the difference

55 In contrast, dialysis with chelerythrine, a PKC inhibitor, did not alter the run-up

56 Application of chelerythrine, a potent PKC inhibitor, to the presumptiv

57 , a reactive oxygen species (ROS) scavenger, chelerythrine, a protein kinase C (PKC) inhibitor, and l

58 by diazoxide was not blocked by 5 micromol/L chelerythrine, a protein kinase C antagonist, given eith

59 inine, a nitric oxide synthase inhibitor, or chelerythrine, a protein kinase C inhibitor (both given

60 cell death, all of which were suppressed by chelerythrine, a protein kinase C inhibitor, DPI, a NADP

61 , an NK1 tachykinin receptor antagonist, and chelerythrine, a protein kinase C inhibitor.

62 sphorylation was substantially attenuated by chelerythrine, a protein kinase C-selective inhibitor.

63 Administration of chelerythrine, a specific PKC inhibitor, completely abol

64 Administration of chelerythrine, a specific PKC inhibitor, completely abol

65 Furthermore, chelerythrine, a specific PKC inhibitor, prevented this

66 were blocked almost completely by 25 microM chelerythrine, a specific, noncompetitive PKC inhibitor.

67 Pretreatment with pertussis toxin and chelerythrine abolished the protective effects of both r

68 athways by administration of the PKC blocker chelerythrine abrogated the ischemic protection afforded

69 Also, treatment with chelerythrine abrogated the potentiating effect of AngII

70 tly inhibited by the PKC catalytic inhibitor chelerythrine added before and concomitant with EPO.

71 A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whol

72 n IL-1 receptor antagonist, a PKC inhibitor (chelerythrine), an IP3 receptor inhibitor (2-aminoethoxy

73 Chelerythrine, an inhibitor of PKC, inhibited activation

74 Chelerythrine, an inhibitor of PKMzeta, and the inductio

75 Chelerythrine, an inhibitor of PKMzeta, reversed the coc

76 Repeated administration of PKC inhibitors chelerythrine and 1-(5-isoquinolinesulfonyl)-2-methylpip

77 Chelerythrine and 100 nM okadaic acid, which inhibited e

78 eversible by the protein kinase C inhibitors chelerythrine and 2-[1-(3-dimethylaminopropyl)-1H-indol-

79 ited by the protein kinase C (PKC) inhibitor chelerythrine and activated by the phorbol ester phorbol

80 In addition, chelerythrine and angoline did not inhibit [3H]phorbol 1

81 rotein kinase C-specific inhibitors, such as chelerythrine and bisindolylmaleimide I, did not reduce

82 was blocked by the selective PKC inhibitors chelerythrine and bisindolylmaleimide I.

83 Chelerythrine and bisindolylmaleimide-1 (Bis), two inhib

84 ited by the protein kinase C (PKC) inhibitor chelerythrine and by anti-TRPC1 antibodies indicating th

85 In addition, PKC inhibition by chelerythrine and calphostin C (500 nmol/L) prevented ce

86 ioned hearts treated with the PKC inhibitors chelerythrine and calphostin C.

87 ion was also prevented by the PKC inhibitors chelerythrine and calphostin C.

88 Inhibitors of protein kinase C (PKC) chelerythrine and calphostin-C decreased the amplitude o

89 on PKC activation because it was blocked by chelerythrine and GF109203X, two PKC inhibitors.

90 on is promoted by activating ligands such as chelerythrine and harmine.

91 We then examined the effect of chelerythrine and phosphatase inhibition with phenylarsi

92 ts overcome the effects of blocking PKC with chelerythrine and resulted in a rescue of the wing morph

93 was markedly inhibited by the PKC inhibitors chelerythrine and RO-31-8220.

94 in, or the protein kinase C (PKC) inhibitors chelerythrine and staurosporine or by the angiotensin-co

95 Protein kinase C inhibitors, chelerythrine and staurosporine, decreased the constrict

96 yjdF riboswitch in complex with activating (chelerythrine) and nonactivating (lumichrome) ligands.

97 have been reported in studies conducted with chelerythrine, and alteration of PKC activity has been c

98 PTK), genistein, and protein kinase C (PKC), chelerythrine, and bisindolylmaleimide GF 109203X.

99 ant (TAM67) were exposed to calphostin C and chelerythrine, and c-jun expression was monitored at bot

100 ced Hsp70i message levels, whereas SB203580, chelerythrine, and curcumin reversed the subcellular red

101 nates, which was attenuated by PKC inhibitor chelerythrine, and enhanced evoked potentials during cos

102 ed TRPC5 channel activity was potentiated by chelerythrine, and inhibited by PDBu, PIP(2), and PIP(3)

103 nt pharmacological manipulations (L-NA, MPG, chelerythrine, and lavendustin A) produced similar inhib

104 opionyl glycine, protein kinase C antagonist chelerythrine, and mitochondrial K(ATP) channel closer 5

105 ls treated with calphostin C, staurosporine, chelerythrine, and PKCalpha antisense, respectively.

106 C), PKC (including pseudosubstrate peptides, chelerythrine, and the alpha/beta isoform-specific inhib

107 tor wortmannin, the protein kinase C blocker chelerythrine, and the mitogen activated protein kinase

108 We found that the protein kinase C inhibitor chelerythrine antagonized BMP7-induced protection agains

109 r dialysis accelerated this current, whereas chelerythrine antagonized it, suggesting the involvement

110 ver in cell-attached patches pretreated with chelerythrine, application of 100 nM Ang II activated Ic

111 The cellular effects of chelerythrine are not due to either direct or indirect i

112 nt to downregulate PKC and the PKC inhibitor chelerythrine, arguing that PKCepsilon plays a critical

113 tudies use zeta inhibitory peptide (ZIP) and chelerythrine as inhibitors of PKMzeta to block long ter

114 d by the administration of the PKC inhibitor chelerythrine at a dose of 5 mg/kg (group VI) (particula

115 Administration of the PKC inhibitor chelerythrine at a dose of 5 mg/kg before the first O on

116 study tested whether inhibition of PKC with chelerythrine before daily stress would protect prefront

117 ol esters and is inhibited by staurosporine, chelerythrine, bisindolylmaleimide I, calphostin C, and

118 Interestingly, whereas chelerythrine blocked maintenance of the enhancement, Bi

119 Chelerythrine blocked sympathoexcitatory responses to An

120 of 1 microm bisendolylmaleimide or 1 microm chelerythrine, both protein kinase C inhibitors, potenti

121 dependence, was blocked by pretreatment with chelerythrine but not by NMLA, ddA, TMB-8, or Quin-2.

122 ase C inhibitors (GF109203x, calphostin C or chelerythrine) but not by tyrosine kinase inhibitors (ty

123 ited by the protein kinase C (PKC) inhibitor chelerythrine, but not by the protein kinase A (PKA) inh

124 This effect of PKC epsilon was prevented by chelerythrine, by the specific PKC epsilon peptide antag

125 ptide 5-24) and protein kinase C inhibitors (chelerythrine, calphostin C, and peptide 19--63) did not

126 o different PKC inhibitors, calphostin C and chelerythrine; calphostin C also blocked the fenoldopam-

127 First, chelerythrine causes dose-dependent inhibition of betaII

128 Inhibition of protein kinase C (PKC) with chelerythrine (CHE, 2 micromol/L) completely abrogated b

129 re-ischaemic blockade of PKC was achieved by chelerythrine (Chel) in male (M + C) and female (F + C)

130 ase C inhibitors Ro-31-8220 (1-10 microm) or chelerythrine chloride (1-20 microm).

131 inhibitors [staurosporine (5 micromol/L) and chelerythrine chloride (10 micromol/L)], and a replicati

132 rs bisindolylmaleimide I (BIM; 30 microM) or chelerythrine chloride (100 microM) through a microdialy

133 gated by prior inhibition of either PKC with chelerythrine chloride (5 mg/kg) or of TKs with lavendus

134 0mg/kg, s.c.), midazolam (2mg/kg, i.p.), and chelerythrine chloride (a non-specific PKC inhibitor, 10

135 Chelerythrine chloride (CC) (0.5 micromol/L) inhibited c

136 tors bisindolylmaleimide I (BIS; 100 nM) and chelerythrine chloride (CHE; 25 microM) and was not mimi

137 the protein kinase C group A and B isoforms, chelerythrine chloride (chelerythrine), to enhance the k

138 Inhibition of PKC by chelerythrine chloride abrogated the thrombin-induced GD

139 exposure to the protein kinase C inhibitors chelerythrine chloride and calphostin C.

140 kinase inhibitor ML-7 and the PKC inhibitors chelerythrine chloride and rottlerin.

141 the effects of protein kinase C inhibitors (chelerythrine chloride and sphingosine) or of chronic tr

142 In contrast, chelerythrine chloride and synthetic myristoylated pepti

143 PKC inhibition by chelerythrine chloride application phase advances the in

144 y selective protein kinase C (PKC) inhibitor chelerythrine chloride leads to profound cell cycle arre

145 ally inhibited by the specific PKC inhibitor chelerythrine chloride or by downregulation of PKC with

146 e specific protein kinase C (PKC) inhibitors chelerythrine chloride or calphostin C completely blocke

147 I(Na) were antagonized by the PKC inhibitors chelerythrine chloride or staurosporine or by down-regul

148 nt of cells with PKC translocation inhibitor chelerythrine chloride suppressed the induced extracellu

149 n the side ipsilateral to the injection when chelerythrine chloride was administered intrathecally be

150 se (U0126) and broad spectrum PKC inhibitor (chelerythrine chloride) and decreased cell proliferation

151 ) inhibitor (10.0 mum Ro 31-8220 or 30.0 mum chelerythrine chloride) attenuated cocaine seeking.

152 e, a specific MitoKATP channel inhibitor, or chelerythrine chloride, a PKC inhibitor, during diazoxid

153 Finally, treatment of Jurkat cells with chelerythrine chloride, a protein kinase C inhibitor, pr

154 Furthermore, chelerythrine chloride, a selective protein kinase C (PK

155 The protein kinase C (PKC) inhibitor, chelerythrine chloride, also reduced excitatory amino ac

156 Chelerythrine chloride, an inhibitor of protein kinase C

157 tin C, a blocker of the PMA binding site, or chelerythrine chloride, an inhibitor of the active site,

158 orylation in monocytes, and pertussis toxin, chelerythrine chloride, and staurosporine significantly

159 hemistry to examine whether a PKC inhibitor, chelerythrine chloride, blocks the enhanced phosphorylat

160 taurosporine and the PKC-selective inhibitor chelerythrine chloride, but was activated by the phospha

161 o selective inhibitors of PKC, GF109203X and chelerythrine chloride, effectively block the phosphoryl

162 was inhibited by pertussis toxin, U73122, or chelerythrine chloride, inhibitors of Gi-protein, phosph

163 bited by the PKC inhibitors calphostin C and chelerythrine chloride.

164 ibitor Rp-cAMP or protein kinase C inhibitor chelerythrine chloride.

165 n, but these increases could be prevented by chelerythrine chloride.

166 ent with a protein kinase C (PKC) inhibitor, chelerythrine chloride; the FP receptor antagonist, AL-8

167 On the other hand, chelerythrine (CHT), a documented potent PKC inhibitor,

168 The same dose of chelerythrine completely prevented the DETA/NO-induced l

169 DAMGO-tolerant paws was acutely reversed by chelerythrine, ddA, TMB-8, or Quin-2 but not by NMLA.

170 tivation by PIP(2) whereas the PKC inhibitor chelerythrine decreased SOC stimulation by PIP(2).

171 reporter assay in B. subtilis, we found that chelerythrine-dependent activation is insensitive to mut

172 Chelerythrine did not affect baseline perfusion pressure

173 Further, chelerythrine did not inhibit 12-O-tetradecanoylphorbol

174 t), but the protein kinase C (PKC) inhibitor chelerythrine did not inhibit either the OAG- or ET-1-in

175 The protein kinase C (PKC) inhibitor chelerythrine did not prevent channel activation by OAG

176 r U73122, nor the protein kinase C inhibitor chelerythrine diminished the effect of amitriptyline.

177 ions of thiolic antioxidants fully prevented chelerythrine-driven caspase activation and necrotic-lik

178 er, reducing PKC activity by inhibition with chelerythrine during chronic exposure to ethanol or down

179 ate IPC, but blockade of PKC activation with chelerythrine during IPC blocked its neuroprotection.

180 was entirely Cl- dependent, but part of the chelerythrine effect was Cl- independent.

181 eta inhibitory peptide) or the PKC inhibitor chelerythrine erased the memory for long-term sensitizat

182 apses on cells loaded with the PKC inhibitor chelerythrine exhibited PTP followed by a significant de

183 wortmannin for phosphoinositide 3-kinase and chelerythrine for protein kinase C).

184 whereas pretreatment with the PKC inhibitor chelerythrine (given at doses that have previously been

185 In contrast, neither losartan nor chelerythrine had any effect on mEPSCs or puff NMDA curr

186 Protein kinase C inhibition (chelerythrine) had no effect.

187 , as a related benzophenanthridine alkaloid, chelerythrine, has been reported to mediate a variety of

188 ults uncover a novel biochemical property of chelerythrine, i.e. activation of MEKK1- and MKK4-depend

189 icroM), calphostin C (IC50 = 2.4 microM), or chelerythrine (IC50 = 8.0 microM).

190 or disruption of caveolae but was blocked by chelerythrine, implicating protein kinase C, but not pho

191 When rabbits were given 5 mg/kg of chelerythrine in the absence of O/R (group V, n = 5), th

192 In contrast, the PKC inhibitor chelerythrine increased the activity of channel currents

193 kinase C (PKC) activity by calphostin C and chelerythrine increased the activity of the exchanger in

194 Chelerythrine increases sphingomyelinase activity and en

195 rsed by the protein kinase C (PKC) inhibitor chelerythrine indicating a G-protein pathway inhibits ch

196 In addition, chelerythrine induced apoptosis that was blocked by the

197 Compared with staurosporine, chelerythrine induced stronger caspase activation detect

198 Biochemically, chelerythrine induced the activation of caspases.

199 Here we report that chelerythrine induced time- and dose-dependent activatio

200 e, dithiothreitol, and glutathione, impaired chelerythrine-induced JNK1 and p38 activation.

201 Inhibition of PKC using chelerythrine inhibited the activities of both MMP-2 and

202 Here, we show that neither ZIP nor chelerythrine inhibits PKMzeta in cultured cells or brai

203 In addition, microinjection of losartan or chelerythrine into the PVN substantially reduced blood p

204 Third, chelerythrine leads to selective loss of betaII PKC duri

205 Pre-treatment with the PKC inhibitor, chelerythrine, markedly increased TRPC6 channel activity

206 of thiolic antioxidants partially prevented chelerythrine-mediated cytotoxicity and allowed cells to

207 Ultrastructural analysis revealed that chelerythrine-mediated cytotoxicity was compatible with

208 , several lines of evidence demonstrate that chelerythrine-mediated G2 phase arrest results from sele

209 Fourth, chelerythrine mediates activation-dependent degradation

210 7, as well as selective inhibition of PKC by chelerythrine, mimics and occludes the maintenance phase

211 from a variety of mammalian species, neither chelerythrine nor angoline inhibited activity with high

212 the effects of herbimycin A, wortmannin, and chelerythrine on iC5b67-induced PMN chemotaxis, iC5b67 s

213 observe any significant inhibitory effect of chelerythrine on the activities of PKC isozymes present

214 o PKC antagonists (D-erythro-sphingosine and chelerythrine) on input-output (I-O) relations in the Sc

215 of protein kinase C such as calphostin C and chelerythrine or (b) chronic pre-exposure to the non-tum

216 he presence of protein kinase C antagonists, chelerythrine or bis-indolylmaleimide hydrochloride (GF

217 Following the addition of chelerythrine or calphostin C to WEHI-231 cells, ceramid

218 Rats were acutely pretreated with chelerythrine or glibenclamide, selective blockers of PK

219 12(S)HETE, as was PKCbeta in the presence of chelerythrine or Go-6983.

220 om LY294002, and was unaffected by 10 microm chelerythrine or incubating cells in pertussis toxin (PT

221 toxicity was also abolished by calphostin C, chelerythrine or l-NAME.

222 PKMzeta inhibition by chelerythrine or myristoylated zeta inhibitory peptide s

223 utely reversed by TMB-8 or Quin-2 but not by chelerythrine or NMLA.

224 ocynin, the protein kinase C (PKC) inhibitor chelerythrine or staurosporin or the removal of extracel

225 y superoxide dismutase, diphenyleneiodonium, chelerythrine, or removal of extracellular Ca2+.

226 tively; P<0.01), which was reversed by NAD+, chelerythrine, or superoxide dismutase.

227 promote cell growth and reduce apoptosis by chelerythrine (p<0.05 versus control).

228 rabbit hearts inhibition of PKCepsilon with chelerythrine, p38 MAP kinase, with SB203580 and JUN kin

229 e particulate fraction and pretreatment with chelerythrine (PKC inhibitor) blocked the protective eff

230 10%), an effect that could be eliminated by chelerythrine preincubation.

231 The protein kinase C antagonist chelerythrine prevented bile acid-stimulated cFLIP-L and

232 alone or in combination with midazolam, and chelerythrine prevented the development of morphine tole

233 In the presence of propranolol, chelerythrine prevented the increase of I(Cl(swell)) by

234 incubation with the protein kinase inhibitor chelerythrine prevented the PMA effects; and (3) a hydro

235 eatment of cells with the pan-PKC inhibitor, chelerythrine, prevented the activation of endothelial a

236 This effect was sensitive to chelerythrine (protein kinase C inhibitor) and cypermeth

237 or), uric acid (scavenger of peroxynitrite), chelerythrine (protein kinase C inhibitor), N(G)-nitro-L

238 eated with 100 nmol/L GF109203X or 5 mumol/L chelerythrine (protein kinase C inhibitors), neither 5 U

239 of PKC with staurosporine, calphostin C, and chelerythrine reduced cell proliferation to 7%, 31%, and

240 In rabbit hearts SB203580 and chelerythrine reduced Hsp70i message levels, whereas SB2

241 However, although chelerythrine reinstates the chronic morphine-induced lo

242 tivator phorbol 12, 13-dibutyrate (PDBu) and chelerythrine, respectively, decreased and increased NP(

243 s or the newly identified Bcl-X(L) inhibitor chelerythrine restores cellular sensitivity to injury an

244 T5823, and protein kinase C (PKC) inhibitors chelerythrine, Ro318220, and PKC-epsilon peptide antagon

245 GF109203X, Ro 31-8220, calphostin C, and chelerythrine (selective protein kinase C inhibitors) ha

246 ceptors with losartan or inhibiting PKC with chelerythrine significantly decreased the frequency of N

247 Second, chelerythrine specifically inhibits betaII PKC-mediated

248 Inhibition of protein kinase C (PKC) using chelerythrine, staurosporine, or calphostin C inhibited

249 protein kinase inhibitors staurosporine and chelerythrine stimulated a normally silent component of

250 To the contrary, chelerythrine stimulated PKC activity in the cytosolic f

251 not by the protein kinase C (PKC) inhibitor chelerythrine, the adenylyl cyclase inhibitor 2',5'-dide

252 kinase C (PKC) inhibitors staurosporine and chelerythrine, the phospholipase C (PLC) inhibitors D609

253 up A and B isoforms, chelerythrine chloride (chelerythrine), to enhance the killing effects of ionizi

254 Chelerythrine triggered an early plasma membrane leakage

255 reover, the inhibition of caspases prevented chelerythrine-triggered necrotic-like cell death.

256 Chelerythrine was a weak inhibitor of PKM-zeta (K(i) = 7

257 When the protein kinase C (PKC) inhibitor chelerythrine was coadministered with adenosine, the PAE

258 Chelerythrine was selected for further studies based on

259 The associated kinase was inhibited by chelerythrine, with half-maximal inhibition at approxima